Numerous neurodegenerative diseases are characterized by intracellular aggregation of hyperphosphorylated tau protein,
1 including Alzheimer disease (AD), in which pathological tau deposition primarily manifests as neurofibrillary tangles.
2 Tau is an attractive therapeutic target in AD, as both neuropathological
3,4 and tau positron emission tomography (PET)
5,6 studies demonstrate significant correlations between cerebral tau pathology and clinical disease severity.